We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Reporting of Study Comparing Casodex, Eulexin Is Questioned

  • Robert J. Spiegel, MD
Jan 1, 1996
Volume: 
5
Issue: 
1

I would like to call your attention to a misleading statement
that appeared in the Industry Watch section of the October, 1995,
issue of Oncology News International under the title "Casodex
Approved for Prostatic Cancer" (page 23).

The statement reads: "The company reports that after a median
follow-up of 95 weeks, Casodex [in combination with an LHRH agonist]
was similar to flutamide (Eulexin) in its effect on survival."

You should be aware that the Professional Information Brochure
for Casodex from Zeneca Pharmaceuticals actually states the following:
"At a median follow-up of 95 weeks, time to treatment failure
with Casodex-LHRH analog therapy was not dissimilar when compared
to Flutamide-LHRH analog therapy" (page 4).

Primary Endpoint

This clarification is quite important, as the pivotal trial that
compared Casodex (bicalutamide) to Eulexin and formed the basis
of Casodex's approval by the FDA did not, in fact, show improvement
in either time to disease progression or survival.

Rather, this study utilized as its primary endpoint, the unusual
endpoint of time to treatment failure. This is defined in the
study as "withdrawal from the study for any reason."
Time to treatment failure is generally not accepted by the medical
community as a primary efficacy endpoint.

In contrast, Schering-Plough's Eulexin (flutamide) has been shown
in several major studies to delay progression and extend survival
time for advanced prostate cancer patients. One pivotal study
conducted by the National Cancer Institute showed that, in patients
with minimal metastatic bone disease, Eulexin, when initiated
with an LHRH agonist, delayed progression by 29 months and increased
overall survival by 19 months.

Side Effects

In a follow-up item on the approval of Casodex that appeared in
the November, 1995, issue of Oncology News International (page
24), your reporter refers to findings from the Casodex study on
side effects.

Pages

  • 1
  • 2
  • next ›
  • last »

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.